Street portrait of smiling senior man

Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Image from the 22nd February 2017 of a billboard that announces that Nasdaq Stockholm welcomes Oncopeptides.

Investor news

See our latest Investor presentations, webcast, transcripts and interviews.

To the archive

Press release - July 22, 2024

First patient enters Oncopeptides study aiming to gain real-world insights from Pepaxti in Germany

Read press release

David Augustsson - Director of Corporate Affairs

Investor Relations Contact

 

David Augustsson

Director of Corporate Affairs

david.augustsson@oncopeptides.com
+46 762 29 38 68

Oncopeptides AB

The share

Oncopeptides is listed on Nasdaq Stockholm Small Cap under the trade symbol ONCO, since February 22, 2017.

All share information

Hand pointing at stock exchange numbers in Swedish financial newspaper

Financial reports

See all of our financial reports together with related documents and webcasts.

To the archive

Upcoming events

2024-07-15 - 2024-08-13

Silent Period

Other

2024-08-14

Interim Report Q2 2024

Report

2024-10-08 - 2024-11-06

Silent Period

Other

Oncopeptides via e-mail